Gastroenterology-Focused Preclinical CRO

KCI Biotech provides Preclinical gastroenterology CRO services. We conduct in vivo pharmacology and Preclinical GI efficacy testing across multiple laboratory animal species.

Why Use Animal Models in Digestive Disease Research

Gastrointestinal mucosal barrier functions, motility reflexes, and hepatobiliary secretions involve systemic interactions that cannot be simulated in vitro. In vivo disease models are necessary to quantify tissue protection, inflammatory response, and organ recovery. As a gastroenterology CRO, KCI Biotech performs pharmacodynamic evaluations following standardized protocols.

Our Portfolio of Digestive System Disease Models

KCI Biotech provides established animal models covering mucosal injury, hepatobiliary conditions, pancreatitis, and functional gastrointestinal disorders:

Gastric & Mucosal Injury Models

• Gastric ulcer animal models: Acetic acid-induced gastric ulcers and acetic acid + indomethacin-induced refractory ulcers.
• Aspirin-induced acute gastric mucosal erosion and bleeding.
• Sodium deoxycholate (DOC-Na) + ammonia + indomethacin-induced atrophic gastritis.

Hepatobiliary & Pancreatic Disease Models

• Bile duct ligation (BDL) and ANIT-induced cholestasis supporting our Primary biliary cholangitis CRO services.
• Trinitrobenzene sulfonic acid (TNBS)-induced primary sclerosing cholangitis.
• Acute pancreatitis induced by rain frog peptide or sodium bovine cholate, alongside Chronic pancreatitis animal models induced by rain frog peptide.

Functional Gastrointestinal & Emesis Models

• 5-Fluorouracil (5-Fu)-induced diarrhea models for Antidiarrheal drug efficacy testing.
• Cisplatin-, semaglutide-, and GLP-1RA-induced vomiting models serving as translational CINV animal models in rodents and ferrets.

Comprehensive Gastroenterology CRO Solutions & Collaboration

Portfolio: A variety of specific digestive disease models within a catalog of 500+ validated animal models.

Facilities & Species: Over 40,000 m² of AAALAC-accredited facilities supporting mice, rats, ferrets, dogs, and non-human primates.

Evaluation Platforms: Serum biochemistry (ALT, AST, amylase, lipase), ulcer index quantification, and organ histopathology.

Track Record: Supported over 200 IND submissions (NMPA/FDA) for 1000+ pharmaceutical and biotechnology clients.

KCI Biotech provides customized protocol designs and experimental endpoints for preclinical gastrointestinal drug programs. Contact our technical team for study consultations and project planning.